Literature DB >> 3698171

Acute neurological toxicity of intrathecal cytosine arabinoside. A case report.

S M Crawford, G J Rustin, K D Bagshawe.   

Abstract

A patient developed severe neurological toxicity, with peripheral and cerebral components and hyponatraemia following one intrathecal injection of 80 mg cytosine arabinoside. The severity of his symptoms may reflect heavy prior neurotoxic chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3698171     DOI： 10.1007/bf00293998

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Paraparesis following intrathecal cytosine arabinoside: a case report with neuropathologic findings.

Authors:  A C Breuer; S W Pitman; D M Dawson; W C Schoene
Journal:  Cancer       Date:  1977-12       Impact factor: 6.860

Review 2.  Paraplegia following intrathecal chemotherapy.

Authors:  J H Saiki; S Thompson; F Smith; R Atkinson
Journal:  Cancer       Date:  1972-02       Impact factor: 6.860

3.  Nervous system toxic effects of cancer therapy.

Authors:  I D Goldberg; W D Bloomer; D M Dawson
Journal:  JAMA       Date:  1982-03-12       Impact factor: 56.272

4.  Paraplegia following intrathecal cytosine arabinoside.

Authors:  L Wolff; J Zighelboim; R P Gale
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

5.  Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study.

Authors:  M D Winkelman; J D Hines
Journal:  Ann Neurol       Date:  1983-11       Impact factor: 10.422

6.  Central and peripheral myelinopathy associated with systemic neoplasia and chemotherapy.

Authors:  H Mena; J H Garcia; F Velandia
Journal:  Cancer       Date:  1981-10-15       Impact factor: 6.860

7.  Central nervous system metastases of choriocarcinoma. 23 years' experience at Charing Cross Hospital.

Authors:  A Athanassiou; R H Begent; E S Newlands; D Parker; G J Rustin; K D Bagshawe
Journal:  Cancer       Date:  1983-11-01       Impact factor: 6.860

8.  Further advances in the management of malignant teratomas of the testis and other sites.

Authors:  E S Newlands; R H Begent; G J Rustin; D Parker; K D Bagshawe
Journal:  Lancet       Date:  1983-04-30       Impact factor: 79.321

9.  Prophylaxis against hypomagnesaemia induced by cis-platinum combination chemotherapy.

Authors:  V M Macaulay; R H Begent; M E Phillips; E S Newlands
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333
  9 in total
  1 in total

Review 1.  Transverse myelitis.

Authors:  Shin C Beh; Benjamin M Greenberg; Teresa Frohman; Elliot M Frohman
Journal:  Neurol Clin       Date:  2013-02       Impact factor: 3.806
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.